UBS Starts Insmed (INSM) at Buy, 'We see ~60% upside to the current share price'

February 26, 2024 4:22 PM

UBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ: INSM) with a Buy rating and a price target of $46.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found